Moderna secures millions for Ebola vaccine as it searches for life after Covid
Moderna (MRNA) was one of the big beneficiaries of the Covid pandemic, producing tens of billions of dollars in vaccine sales and becoming one of the most carefully watched businesses in biotechnology.
Since then, the task has been to prove that the accomplishment was not a fluke.
As Covid-related revenue fades, investors have increasingly focused on whether Moderna can leverage its mRNA technology to develop the next generation of vaccines and therapies that can drive future growth.
That attempt just got a critical shot in the arm.
As health officials respond to an expanding Ebola Bundibugyo outbreak in Central Africa, the World Health Organization that played a vital role in helping to produce vaccines during the pandemic is pledging additional funds to Moderna and other research institutions.
The outbreak is caused by a type of Ebola that has no recognized vaccinations or therapies.
It's unlikely the funding will be a big near-term revenue driver for Moderna. But it might help validate the company's technology platform and build confidence that its vaccination knowledge goes well beyond Covid.
The company is also working to diversify its business through respiratory vaccines, oncology programs, and infectious disease medicines, and investors have been looking for evidence of development in its pipeline.
The recent fundraising round is one further illustration of how Moderna's platform could be deployed against new global health threats.
"Our goal is to move as fast as we can without compromising safety, and to be as helpful as we can," Moderna CEO Stephane Bancel said, according to Reuters.
Moderna receives major funding for Ebola vaccine development
The Coalition for Epidemic Preparedness Innovations said it will contribute up to $50 million to support Moderna's investigational Ebola vaccine candidate.
The funds will go toward preclinical research, clinical development, and manufacturing. If early results are satisfactory, the funding might also help bring the vaccine into larger research.
Moderna's previous Ebola research in the pre-clinical setting had revealed good findings, the company said. When the business moves to human testing, it is likely to explore whether the vaccine can be provided in one dosage or many doses.
The Ebola initiative is simply a small part of a much wider approach.
Key takeaways for Moderna investors
- CEPI committed up to $50 million to Moderna's Ebola vaccine program.
- There are currently no approved vaccines for Ebola Bundibugyo.
- The funding reduces some development costs associated with the program.
- Positive clinical data could further validate Moderna's mRNA technology platform.
- The announcement supports Moderna's broader strategy of expanding beyond Covid-related products.
Moderna has been working for the last many years to create a pipeline to decrease its reliance on Covid vaccinations. The business already sells an RSV vaccine and is developing flu, combined respiratory, and cancer-related programs.
Related: Flight diverted from the U.S. over ebola virus fears
Success in any of these areas might help offset decreased pandemic-related revenue and open up new ways to develop over the long run.
CEPI is also financing vaccine candidates being developed by the University of Oxford, the Serum Institute of India and the International AIDS Vaccine Initiative.
Why the Ebola outbreak matters
The assistance comes as health officials wrestle with a growing outbreak in the Democratic Republic of Congo and neighboring Uganda.
There are 282 verified cases, including 42 deaths, in Congo, and about 1,100 suspected cases, Reuters said. Confirmed cases and deaths have also been recorded from Uganda.
But Ebola Bundibugyo is different from the Ebola Zaire strain, and that's the issue for researchers.
Merck (MRK) sells Ervebo, an authorized vaccine for Ebola Zaire, but there are no approved vaccines or therapies for Bundibugyo.
That deficit has led to increased funding for vaccine research from governments and global health groups.
The International AIDS Vaccine Initiative is working on a single-dose candidate, based on technology linked to the authorized Ebola vaccine from Merck. Oxford's program is based on technology similar to the Covid vaccine made with AstraZeneca (AZN).
The urgency surrounding the outbreak helps explain why several entities are ramping up development activities.
What the funding could mean for Moderna stock
But for stockholders, the key lesson isn't future sales of Ebola vaccines.
Even if Moderna manages to develop an Ebola vaccine, the financial opportunity would probably be a fraction of what the business achieved during Covid. Ebola outbreaks tend to be small and vaccine purchases tend to be made by governments, charity groups, and emergency stocks rather than large consumer demand.
That means investors are likely to be more focused on what the funding implies about Moderna's long-term prospects.
The CEPI pledge is an external endorsement from a reputable global health organization. It indicates Moderna is still one of the prominent businesses that can quickly produce vaccines for emerging disease threats.
That reputation may well prove more valuable as governments and health groups pour more money into pandemic preparedness.
The investment also allows Moderna to seek another vaccine option without incurring the full expense of research.
While investors should not anticipate any meaningful near-term impact on profitability from the Ebola program, positive clinical data might bolster confidence in the broader pipeline and emphasize the versatility of its mRNA platform.
More support is also coming in to the Ebola response effort. Gavi, the global vaccination alliance, has pledged up to $50 million for response efforts, and the World Bank's Pandemic Fund announced $220 million in grants.
These commitments reflect the expanding global effort to limit the outbreak and prepare for future disease threats.
Moderna's next big milestone will be to advance its vaccine candidate into human development and show it can provide promising safety and efficacy results.
If successful, the program might give another proof point that Moderna's technology platform continues to provide fresh development potential way outside Covid.
Related: Moderna faces $5 billion mRNA patent lawsuit after 'Star Trek' ruling
The Arena Media Brands, LLC THESTREET is a registered trademark of TheStreet, Inc.
This story was originally published June 4, 2026 at 3:00 PM.